Prospective, Multicenter, Randomized, Open-label, Phase 2, Lasting 12 Weeks, Evaluating the Pharmacodynamics, Efficacy and Safety of Basiliximab in Adult Patients With de Novo Renal Transplant Patients at Low Risk Receiving Either a Cumulative Dose Basiliximab 40 or 80 mg in Combination With Cyclosporine Microemulsion, or a Cumulative Dose of 80 mg Basiliximab Without Calcineurin Inhibitor, With Additional Follow-up of 12 Weeks.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Basiliximab (Primary) ; Ciclosporin; Everolimus; Mycophenolate sodium
- Indications Renal transplant rejection
- Focus Pharmacodynamics; Proof of concept; Therapeutic Use
- Acronyms IDEALE
- 05 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.